<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00796354</url>
  </required_header>
  <id_info>
    <org_study_id>NRL920-01/2008 (IBSc)</org_study_id>
    <nct_id>NCT00796354</nct_id>
  </id_info>
  <brief_title>Constipation Associated With Irritable Bowel Syndrome (IBS-C)</brief_title>
  <official_title>A Phase IIIb/IV, Multi-centre, Double-blind, Randomised, Placebo-controlled Parallel Group Study to Compare the Efficacy and Safety of Movicol® With Placebo in Patients With Constipation Associated With Irritable Bowel Syndrome (IBS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-centre, double-blind, randomised, placebo-controlled, parallel group study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be treated for 28 days, with clinical assessments carried out over 2 visits.
      Follow-up will be performed via telephone at a specific interval during the study to
      determine the outcome of unresolved AEs, any new drug-related AEs or any pregnancies. During
      the run-in period and the treatment phase, patients are prohibited from taking prescription
      or over the counter (OTC) laxative medication or constipating medications. Prescription and
      OTC medications not related to constipation are permitted and must be fully documented, but
      any changes (e.g., dosage, regimen) are to be limited as much as possible.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy and safety of Movicol® versus placebo in the relief of constipation associated with IBS.</measure>
    <time_frame>April 2009</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of treatment on other symptoms of IBS.</measure>
    <time_frame>April 2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of treatment on patient's Quality Of Life (QOL).</measure>
    <time_frame>April 2009</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>NRL920</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOVICOL</intervention_name>
    <description>sealed laminated sachet, 1 - 3 sachets daily for 4 weeks</description>
    <arm_group_label>NRL920</arm_group_label>
    <other_name>Macrogol (PEG) 3350</other_name>
    <other_name>sodium chloride</other_name>
    <other_name>sodium bicarbonate</other_name>
    <other_name>potassium chloride</other_name>
    <other_name>acesulfame potassium</other_name>
    <other_name>lemon-lime flavouring</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar Pill</intervention_name>
    <description>sealed laminated sachet, 1 - 3 sachets daily for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sucrose</other_name>
    <other_name>lemon and lime flavour</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and females aged 18 to 80 years inclusive.

          -  Written informed consent obtained.

          -  Females of child-bearing potential must employ an adequate method of contraception and
             must undergo a pregnancy test at Randomisation Visit.

          -  Willing, able and competent to complete the entire study and comply with study
             instructions.

          -  Patients &gt; 50 years old have to have undergone a colonoscopy or computerised
             tomography (CT) after the onset of their IBS-C symptoms or within the last 5 years.

          -  Patient has diagnosed IBS-C using Rome III criteria for the last 3 months, with
             symptom onset at least 6 months prior to diagnosis.

        Exclusion Criteria:

          -  History or evidence of organic disease in the large bowel, intestinal perforation or
             obstruction due to structural or functional disorder of the gut wall, ileus, severe
             inflammatory conditions of the intestinal tract such as Crohn's disease, complicated
             diverticulitis, ulcerative colitis, toxic megacolon and occlusive or subocclusive
             syndrome.

          -  Abdominal pain of unknown cause, not related to IBS.

          -  Previous major abdominal surgery.

          -  IBS subtype other than IBS-C.

          -  Known allergy to polyethylene glycol (PEG) 3350 or known hypersensitivity to any of
             the active substances.

          -  Laxative, drug or alcohol abuse (recent history or within previous 12 months).

          -  Pregnant or lactating females.

          -  Severe or acute disease within 2 weeks prior to the start of the study.

          -  Patients with type I or II diabetes.

          -  Use of other investigational drugs, prescribed or OTC medications affecting
             gastrointestinal function such as anticholinergics, prokinetics, drugs affecting
             motility, anthraquinones, opioids,ondansetron or other 5-HT3 antagonists.

          -  Incomplete Patient Diary Card during the run-in period.

          -  The occurrence of diarrhoea* during the run-in period.

          -  Patients with abnormal laboratory tests, proctoscopy /abdominal ultrasound,
             colonoscopy, sigmoidoscopy or CT that requires further investigation.

          -  Patients with any condition, which, in the Investigator's may put the patient at
             significant risk, may confound the study results, or may interfere significantly with
             the results of the study.

          -  Participation in another clinical study of drugs or devices parallel to or less than 1
             month before study entry, or previous participation in this study.

          -  Employees of the Investigator or study site with direct involvement in the proposed
             study or other studies under the direction of that Investigator or study site, as well
             as family members of the employees or the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Chapman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mike Geraint, MD</last_name>
    <role>Study Director</role>
    <affiliation>Norgine Pharmaceuticals Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gastroenterologie s.r.o.</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EGK.s.r.o, Sanatorium sv. Anny</name>
      <address>
        <city>Praha</city>
        <zip>130 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlickoustecká Nemocnice a.s.</name>
      <address>
        <city>Ústi Nad Orlicí</city>
        <zip>562 18</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hotel Dieu</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63058</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Archet II</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolles</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Krankenhaus-Betriebs-GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>14193</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Gemeinschaftspraxis</name>
      <address>
        <city>Münster</city>
        <zip>48159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharztpraxis für Innere Medizin</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65185</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Genova</name>
      <address>
        <city>Genova</city>
        <zip>6 - 16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Palermo</name>
      <address>
        <city>Palermo</city>
        <zip>129 - 90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slaskie Centrum Osteoporozy</name>
      <address>
        <city>Katowice</city>
        <zip>40-084</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii ul.Rentgena 5</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prosen SMO</name>
      <address>
        <city>Warszawa</city>
        <zip>01-231</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Gastroenterologii i Hepatologii</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sodra Alvsborgs Hospital (SAS)</name>
      <address>
        <city>Borås</city>
        <zip>SE-176-65</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171-76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Marks Hospital</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Attar A, Lémann M, Ferguson A, Halphen M, Boutron MC, Flourié B, Alix E, Salmeron M, Guillemot F, Chaussade S, Ménard AM, Moreau J, Naudin G, Barthet M. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut. 1999 Feb;44(2):226-30.</citation>
    <PMID>9895382</PMID>
  </reference>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2008</study_first_submitted>
  <study_first_submitted_qc>November 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2008</study_first_posted>
  <last_update_submitted>February 15, 2010</last_update_submitted>
  <last_update_submitted_qc>February 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Mike Geraint</name_title>
    <organization>Norgine Pharmaceuticals Ltd</organization>
  </responsible_party>
  <keyword>Constipation</keyword>
  <keyword>Irritable Bowel Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>August 31, 2012</submitted>
    <returned>October 1, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

